|
|
|
 |
FDA Approval Activities for this Drug…
Micardis HCT (telmisartan/hydrochlorothiazide) Tablets, 40 - 12.5 and 80 - 12.5 mg, Boehringer Ingelheim NDA 21-162 11/17/00 11/20/00 11/20/00 | Micardis (telmisartan) Tablets, 20, 40 and 80 mg , Boehringer Ingelheim NDA 20-850/S5 10/23/03 | Micardis (telmisartan) Tablets, 40 and 80 mg , Boehringer Ingelheim NDA 20-850 11/10/98 11/12/98 11/12/98 8/6/01 | Micardis Indication: for the treatment of hypertension. Micardis (telmisartan) Tablets, Boehringer Ingelheim Micardis (telmisartan) Tablets, Boehringer Ingelheim Micardis HCT (telmisartan / hydrochlorothiazide) Tablets, Boehringer Ingelheim | MICARDIS HCT (telmisartan/hydrochlorothiazide) Tablets, Boehringer Ingelheim Pharma, Labeling Revision | MICARDIS (telmisartan) Tablets, Boehringer Ingelheim Pharma, Labeling Revision | Telmisartan Tablets, Watson Labs, Tentative Approval | Micardis (telmisartan) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., New or Modified Indication | Twynsta (telmisartan and amlodipine besylate) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Micardis HCT (telmisartan and hydrochlorothiazide) Tablets, Boerhinger Ingelheim Pharmaceuticals, Inc., Labeling Revision | Twynsta (amlodipine besylate and telmisartan) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision | Micardis (telmisartan) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc, Labeling Revision | Telmisartan and Hydrochlorothiazide Tablets, Watson Laboratories, Inc., Tentative Approval | Twynsta (amlodipine besylate and telmisartan) Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Labeling Revision
  
|